Description |
transcription factor AP-2 alpha |
peroxisome proliferator activated receptor gamma |
Image |
No pdb structure |
|
GO Annotations |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
|
- Alpha-Linolenic Acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic Acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Fenofibrate
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic Acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglixane
- Elafibranor
- T131
- CLX-0921
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
|
Diseases |
|
|
GWAS |
- Amyotrophic lateral sclerosis (sporadic) ( 24529757)
- Breast cancer in BRCA2 mutation carriers ( 23544012)
- Glucose homeostasis traits ( 25524916)
- Iron status biomarkers (ferritin levels) ( 28334935)
- Metabolite levels ( 23823483)
- Ovarian cancer ( 30557369)
- Response to (pegylated) interferon in HBeAg-negative hepatitis B ( 30715261)
- Zinc levels ( 26025379)
|
- Arterial stiffness index ( 31235810)
- Body mass index ( 28892062 25673413 29273807)
- Cholesterol, total ( 25961943)
- Drug-induced liver injury ( 22968431)
- Endometrial cancer ( 30093612)
- Endometrial cancer (endometrioid histology) ( 30093612)
- Eosinophil counts ( 27863252)
- Eosinophil percentage of granulocytes ( 27863252)
- Eosinophil percentage of white cells ( 27863252)
- Fasting blood insulin ( 25631608)
- Fasting blood insulin (BMI interaction) ( 22581228)
- Fasting blood insulin adjusted for BMI ( 25625282)
- Gut microbiota (functional units) ( 27694959)
- HDL cholesterol ( 30275531)
- Heel bone mineral density ( 30598549)
- Hematocrit ( 27863252)
- Hemoglobin concentration ( 27863252)
- High density lipoprotein cholesterol levels ( 29403010)
- Hip circumference adjusted for BMI ( 25673412)
- Idiopathic osteonecrosis of the femoral head ( 31135556)
- LDL cholesterol ( 25961943)
- LDL cholesterol levels ( 30698716)
- LDL cholesterol levels in current drinkers ( 30698716)
- LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716)
- LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716)
- Medication use (drugs used in diabetes) ( 31015401)
- Medication use (HMG CoA reductase inhibitors) ( 31015401)
- Medication use (thyroid preparations) ( 31015401)
- Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) ( 27416945)
- Neutrophil percentage of granulocytes ( 27863252)
- Plasminogen activator inhibitor type 1 levels (PAI-1) ( 22990020)
- Platelet count ( 29403010)
- Potassium levels ( 29403010)
- Sexual dimorphism in anthropometric traits ( 23754948)
- Systemic lupus erythematosus ( 28714469)
- Type 2 diabetes ( 22885922 18372903 24509480 30054458 29358691 30297969 29632382 31118516 20581827 17463246 30718926 17463248 17463249 28869590)
- Type 2 diabetes (adjusted for BMI) ( 29632382)
- Waist circumference ( 31453325)
- Waist circumference variance ( 31453325)
- Waist-hip ratio ( 25673412)
- Waist-to-hip ratio adjusted for BMI ( 26426971)
- Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625)
- Waist-to-hip ratio adjusted for BMI (age <50) ( 26426971)
- Waist-to-hip ratio adjusted for BMI (age >50) ( 26426971)
- Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) ( 28448500)
- Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625)
- Waist-to-hip ratio adjusted for BMI in active individuals ( 28448500)
- Waist-to-hip ratio adjusted for BMI in non-smokers ( 28443625)
- Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971)
- Waist-to-hip ratio adjusted for body mass index ( 25673412 28448500)
|
Interacting Genes |
37 interacting genes:
APC
CASP1
CASP3
CASP6
CITED2
CITED4
CLTC
CSNK2A1
CSNK2B
CTNNB1
DEK
EP300
EPN1
EPN2
EPS15
GSTO2
HIP1
KCTD15
LDLRAP1
MAGI1
MKRN3
MYC
NFKB1
NPM1
PPARG
PRKAA2
PRKD1
RB1
SRA1
SUMO4
SYT1
TP53
UBE2I
VEGFA
WWP1
WWP2
YBX1
|
106 interacting genes:
ALOX15B
ANP32A
APP
BCAS2
BRD8
CDC34
CDK5
CEP350
CNOT1
COPS5
CREBBP
DNTTIP2
EDF1
EGFR
FABP1
FHOD1
FOXO1
GADD45B
GADD45G
GRIP1
HDAC1
HDAC3
HDAC4
HELZ2
HMGA1
IGFBP3
IKBKB
JAZF1
JMJD1C
JUN
JUND
KAT2A
KAT5
KCTD13
KIF11
KIF1A
KLF5
LMO4
LRIF1
MAFF
MAP2K1
MAPK1
MAPK8
MED1
MED24
MFHAS1
MIF4GD
MSX2
MUC1
NCOA1
NCOA2
NCOA3
NCOA4
NCOA6
NCOR1
NCOR2
NFE2L2
NFE2L3
NFKB1
NFKBIB
NR0B1
NR0B2
NR2E3
NR4A1
NR4A2
NRIP1
NSD1
PAK4
PDIA2
PHB2
PML
POU1F1
PPARGC1A
PPM1B
PRKCA
RAD54L2
RANBP9
RB1
RELA
ROBO4
RXRA
RXRB
RXRG
SERPINH1
SFPQ
SIRT1
SMARCD3
STAT6
STUB1
SVIL
SYT1
TFAP2A
TNP1
TRIM24
TRIP4
UBC
UBE2I
USP7
VDR
ZBTB20
ZBTB3
ZBTB5
ZBTB9
ZNF496
ZNHIT3
ZSCAN1
|
Entrez ID |
7020 |
5468 |
HPRD ID |
00128 |
03288 |
Ensembl ID |
ENSG00000137203
|
ENSG00000132170
|
Uniprot IDs |
P05549
|
A0A494C1F9
D2KUA6
E9PFX5
P37231
|
PDB IDs |
|
1FM6
1FM9
1I7I
1K74
1KNU
1NYX
1PRG
1RDT
1WM0
1ZEO
1ZGY
2ATH
2F4B
2FVJ
2G0G
2G0H
2GTK
2HFP
2HWQ
2HWR
2I4J
2I4P
2I4Z
2OM9
2P4Y
2POB
2PRG
2Q59
2Q5P
2Q5S
2Q61
2Q6R
2Q6S
2Q8S
2QMV
2VSR
2VST
2VV0
2VV1
2VV2
2VV3
2VV4
2XKW
2YFE
2ZK0
2ZK1
2ZK2
2ZK3
2ZK4
2ZK5
2ZK6
2ZNO
2ZVT
3ADS
3ADT
3ADU
3ADV
3ADW
3ADX
3AN3
3AN4
3B0Q
3B0R
3B1M
3B3K
3BC5
3CDP
3CDS
3CS8
3CWD
3D6D
3DZU
3DZY
3E00
3ET0
3ET3
3FEJ
3FUR
3G9E
3GBK
3H0A
3HO0
3HOD
3IA6
3K8S
3KMG
3LMP
3NOA
3OSI
3OSW
3PBA
3PO9
3PRG
3QT0
3R5N
3R8A
3R8I
3S9S
3SZ1
3T03
3TY0
3U9Q
3V9T
3V9V
3V9Y
3VJH
3VJI
3VN2
3VSO
3VSP
3WJ4
3WJ5
3WMH
3X1H
3X1I
4A4V
4A4W
4CI5
4E4K
4E4Q
4EM9
4EMA
4F9M
4FGY
4HEE
4JAZ
4JL4
4L96
4L98
4O8F
4OJ4
4PRG
4PVU
4PWL
4R06
4R2U
4R6S
4XLD
4XTA
4XUH
4XUM
4Y29
4YT1
5AZV
5DSH
5DV3
5DV6
5DV8
5DVC
5DWL
5F9B
5GTN
5GTO
5GTP
5HZC
5JI0
5LSG
5TTO
5TWO
5U5L
5UGM
5WQX
5WR0
5WR1
5Y2O
5Y2T
5YCN
5YCP
5Z5S
5Z6S
6AD9
6AN1
6AUG
6AVI
6C1I
6C5Q
6C5T
6D3E
6D8X
6D94
6DBH
6DCU
6DGL
6DGO
6DGP
6DGQ
6DGR
6DH9
6DHA
6E5A
6ENQ
6F2L
6FZF
6FZG
6FZJ
6FZP
6FZY
6ICJ
6IJR
6IJS
6ILQ
6IZM
6IZN
6JQ7
6K0T
6MCZ
6MD0
6MD1
6MD2
6MD4
6MS7
6O67
6O68
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
|
|
Tagcloud (Difference) ? |
|
|
Tagcloud (Intersection) ? |
|